Men Denied Life-Extending Prostate Cancer Drug
In a troubling development for prostate cancer patients in England and Northern Ireland, the life-extending drug abiraterone has not been approved for use through the NHS. This decision has sparked frustration and anger among health advocates and cancer charities, particularly Prostate Cancer UK, which has been vocal about the urgent need for this treatment.
Abiraterone, a medication that helps prevent prostate cancer from spreading, has been available to high-risk patients in Scotland and Wales for the past two years. However, in England and Northern Ireland, it is only offered to men with advanced prostate cancer that has already metastasized. This discrepancy leaves many patients in a precarious situation, as they are denied access to a drug that could significantly improve their chances of survival.